A study conducted by Several American universities have found that HIV patients whose medication regimens were monitored by an innovative ingestible sensor system, responded more adherently to antiretroviral drugs (ARVs) and, in turn, had lower viral loads.
The study, published in the journal The Lancet Ebiomedicine, assessed feasibilitythe acceptability and sustainability of the use of the Proteus Digital Health Feedback (PDHF) information technology system, evaluated its accuracy and assessed its effectiveness in monitoring and improving medication adherence.
“When the patients were first included in our study, they had problems with drug liability. During the course of the study, they frequently expressed that the ingestible sensor technology system provides them with the additional information and support they need to successfully manage their HIV infection,” said Eric Daar, one of the study’s investigators.
The PDHF uses a tiny edible sensor that is over-encapsulated along with the drug.. When ingested, it is detected by a patch with an integrated monitor and sensor worn by the patient. The monitor sends a Bluetooth signal to a mobile device, which in turn sends an encrypted message to a central server, which records in real time that a dose of medication has just been taken.
“After more than two decades of technological improvements, ingestible sensor technology is at the cutting edge, the most modern and precise method based on information technology to measure and control adherence behavior wirelessly and in real time via a mobile device. Our study showed particularly promising results for those who have significant difficulty adhering to antiretroviral medications,” said Honghu Liu, co-principal investigator.